GlobeNewswire Inc. · Oct 5, 2023
BioSenic S.A. : Information on the total number of voting rights and shares
REGULATED INFORMATION
NASDAQ · BIOS
BioPlus Acquisition Corp.
Financial Services · Shell Companies
$10.80
Down-$0.01 (-0.05%)
Updated Aug 16, 2026, 5:27 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 209.07M
- P/E ratio
- 1,249.89
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 5.64K
- Avg. volume
- 37.38K
Price performance
BIOS price history
1M range · 0 trading sessions · Daily adjusted prices
BIOS does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest BIOS news
The latest Smart Investors Daily articles mentioning BIOS.
Stock researchCompany · Overview
BIOS research
Overview
Company profile and research snapshot.
Company profile
BioPlus Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses in the life sciences industry. The company was incorporated in 2021 and is based in New York, New York.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
GlobeNewswire Inc. · Oct 5, 2023
BioSenic S.A. : Information relative au nombre total de droits de vote et d’actions
INFORMATION REGLEMENTEE
GlobeNewswire Inc. · Sep 27, 2023
BioSenic performs further analysis of its phase 2 clinical trial data, leading to an optimal administration scheme for its next late-stage trial of arsenic trioxide in cGvHD
BioSenic performs further analysis of its phase 2 clinical trial data, leading to an optimal administration scheme for its next late-stage trial of arsenic trioxide in cGvHD
GlobeNewswire Inc. · Sep 27, 2023
BioSenic poursuit l'analyse des données de son essai clinique de phase 2, ce qui lui permet de définir un schéma d'administration optimal pour son prochain essai de phase avancée sur l'arsenic trioxide dans le traitement de la cGvHD
INFORMATION PRIVILEGIÉE
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
